Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

  • Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY
  • JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005293/en/

Deciphera Pharmaceuticals Aktie

23,80 €
-0,85 %
Die Deciphera Pharmaceuticals Aktie notiert heute etwas tiefer, mit einem Rückgang von -0,85 %.
Eine Reihe von Buy-Einschätzungen für Deciphera Pharmaceuticals, keine Sell-Einschätzungen in Sicht.
Das von der Community festgelegte Kursziel von 24 € für Deciphera Pharmaceuticals wurde mit dem aktuellen Kurs von 23.8 € erreicht.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare